Drugs / 225Ac-ETN029
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07006727 | Oct 2025 → Aug 2031 expected | digestive system neuroendocrine neoplasm, prostate neuroendocrine neoplasm, pulmonary large cell neuroendocrine carcinoma, small cell lung carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 225Ac-ETN029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07006727 ↗ |
| Modality | Other / unclassified | “Radioligand therapy” NCT07006727 ↗ |